New phase I/II clinical trial : everolimus and paclitaxel albumin-stabilized nanoparticle in treating breast cancer


The Cancer Institute of New Jersey and the National Cancer Institute launched in July 2009 a new phase I/II clinical trial involving a nanoparticle formulation, which is now registered in the Clinicaltrials.gov database under reference NCT00934895. According to this page, “this phase I/II trial is studying the side effects and best dose of everolimus when given together with paclitaxel albumin-stabilized nanoparticle formulation and to see how well it works in treating women with locally advanced or metastatic breast cancer.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: